The Big Spend-Down: US FDA Eyes $159M Reduction In Carryover User Fees
Executive Summary
Agency will substantially reduce amount of human drug and biosimilar user fees that it carries over from year to year by the end of fiscal 2022; carryover generic drug and biosimilar fees will go toward hiring term-limited employees and building capacity, but a technical issue will keep FDA from accessing $79m in PDUFA fees.
You may also be interested in...
US FDA Exploring Furlough Possibility If User Fee Bill Not Enacted In Time
Furloughs would allow affected FDA staff to remain employed, while a layoffs would require affected workers to be rehired.
US FDA Exploring Furlough Possibility If User Fee Bill Not Enacted In Time
Furloughs would allow affected FDA staff to remain employed, while a layoffs would require affected workers to be rehired.
MDUFA V: US FDA Staff Could See September Lay-Off Notices
The notices normally would go out on 1 August, but unspent user fee funds may be able to sustain work for a few weeks if the program expires.